Pfizer: Ovarian Neoplasms trials
The registry lists 38 Ovarian Neoplasms studies with Pfizer as lead sponsor. 1 are open to participants now and 18 have results posted.
Phase 1 26Phase 2 11Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Sigvotatug Vedotin in Advanced Solid TumorsRecruitingNCT04389632Phase 1
- Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian CancerTerminatedNCT05261490Phase 1/2Results posted
- A Study of PF-07260437 in Advanced or Metastatic Solid TumorsTerminatedNCT05067972Phase 1Results posted
- Study of PF-07263689 in Participants With Selected Advanced Solid TumorsTerminatedNCT05061537Phase 1Results posted
- Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and AnorexiaCompletedNCT04803305Phase 1Results posted
- A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid TumorsCompletedNCT04672460Phase 1Results posted
- Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid TumorsTerminatedNCT04628780Phase 1Results posted
- A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)CompletedNCT03657043Phase 2Results posted
- Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)TerminatedNCT03642132Phase 3Results posted
- A Study of PF-06873600 in People With CancerTerminatedNCT03519178Phase 1/2Results posted
- Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.CompletedNCT03245736Phase 2Results posted
- Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)TerminatedNCT02718417Phase 3Results posted
- A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)CompletedNCT02580058Phase 3Results posted
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02552121Phase 1/2Results posted
- A Study Of PF-06647020 For Adult Patients With Advanced Solid TumorsCompletedNCT02222922Phase 1Results posted
- A Study Of PF-06664178 In Patients With Advanced Solid TumorsTerminatedNCT02122146Phase 1Results posted
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02001623Phase 1/2Results posted
- A Study Of PF-06263507 In Patients With Advanced Solid TumorsTerminatedNCT01891669Phase 1Results posted
- A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerTerminatedNCT01849874Phase 3Results posted
- A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Phase 1
- A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.TerminatedNCT06546553Phase 1
- A Study of SGN-MesoC2 in Advanced Solid TumorsTerminatedNCT06466187Phase 1
- A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsTerminatedNCT06285097Phase 1
- A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2Active, not recruitingNCT06003231Phase 2
- Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.WithdrawnNCT05905341Phase 1
- A Study of SGN-ALPV in Advanced Solid TumorsTerminatedNCT05229900Phase 1
- A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsTerminatedNCT05194072Phase 1
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingActive, not recruitingNCT05059522Phase 3
- Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.CompletedNCT04881045Phase 1
- A Study of SGN-STNV in Advanced Solid TumorsTerminatedNCT04665921Phase 1
- PF-07104091 as a Single Agent and in Combination TherapyActive, not recruitingNCT04553133Phase 2
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
- Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.TerminatedNCT04152018Phase 1
- A Safety Study of SGN-CD47M in Patients With Solid TumorsTerminatedNCT03957096Phase 1
- A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal CancerWithdrawnNCT02836028Phase 2
- Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor PatientsCompletedNCT01363232Phase 1
- Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube CancerCompletedNCT00074867Phase 2
- Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian CancerTerminatedNCT00051584Phase 2